DMII logo

DRUGS MADE IN AMERICA ACQUIS

DMIINASDAQ
🏆 #2691 by market capUS Equity
$10.18▲ $0.01 (+0.05%)
Market closed · at close
🔔
Track DMII
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.1%
7d▲ 0.1%
14d▲ 0.1%
30d▲ 0.5%
ytd▲ 3.1%
1y—
🏦Market Cap
$648M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$10.08 – $10.33
52-Week Range
$9.86 – $10.33
Volume
$2.32B
Avg Volume
$1.63B
Shares Outstanding
63.7M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$51M
Last Q Revenue
$12M
P/E Ratio
0.3
P/S Ratio
0.0x
EPS (TTM)
$0.26
Dividend Yield
0.00%
Dilution (1yr)
−79.1%

Why Investors Own DMII

  • ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DMII logo

DRUGS MADE IN AMERICA ACQUIS

DMII
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$1M▲ +757.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$1M▲ +424.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.3M▼ −79.1% YoY
StockOtter · stockotter.space

About DRUGS MADE IN AMERICA ACQUIS

Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$10.07
▼ −1.1% Downside
High Target$11.26
Low Target$8.74
Based on 33 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

DRUGS MADE IN AMERICA ACQUIS tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift DMII price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

DRUGS MADE IN AMERICA ACQUIS announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.